abivertinib   Click here for help

GtoPdb Ligand ID: 10044

Synonyms: AC0010 | AC0010MA | avitinib (superceded INN)
Compound class: Synthetic organic
Comment: Abivertinib (AC0010) is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [2]. It may also inhibit BTK, thus offering extended clinical utility [3]. We show the structure for the free base form of the compound.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 98.41
Molecular weight 487.21
XLogP 4.44
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(c(c2)F)N2CCN(CC2)C)nc2c1cc[nH]2
Isomeric SMILES C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(c(c2)F)N2CCN(CC2)C)nc2c1cc[nH]2
InChI InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
No information available.
Summary of Clinical Use Click here for help
Clinical efficacy of AC0010 as an anti-cancer candidate is being evaluated in a number of clinical trials. Phase 1 results in NSCLC were published in mid 2018 [1]. The most advanced trial is a Phase 3 study that is designed to compare AC0010 and chemotherapy (pemetrexed/cisplatin) in patients with advance NSCLC whose disease has progressed following prior EGFR inhibitor therapy (NCT03058094).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03058094 A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI Phase 3 Interventional Hangzhou ACEA Pharmaceutical Research Co., Ltd.